BTSG
Brightspring Health Services Inc
$
22.390
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
22.420
Open
21.750
VWAP
22.00
Vol
3.04M
Mkt Cap
3.97B
Low
21.580
Amount
66.77M
EV/EBITDA(TTM)
14.88
Total Shares
177.15M
EV
6.32B
EV/OCF(TTM)
23.54
P/S(TTM)
0.36
BrightSpring Health Services, Inc. provides home and community-based pharmacy and health solutions for populations in need of specialized and/or chronic care. Through the Company’s service lines, including pharmacy, home health care and primary care, and rehabilitation and behavioral health, it provides integrated care and clinical solutions in all 50 states to over 450,000 customers, clients and patients daily. With a focus on senior and specialty patients, the Company’s platform provides pharmacy and provider services (both clinical and supportive care in nature) in lower-cost home and community settings largely to medicare, medicaid, and commercially insured populations. It delivers services through two reportable segments: Pharmacy Solutions and Provider Services. It provides pharmacy services when and where demanded and as required by customers and patients in their homes and communities, often in coordination with its provider’s services.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
3.16B
+8.72%
0.275
+149.93%
3.33B
+8.96%
0.310
+40.85%
3.24B
+12.51%
0.251
+32.04%
Estimates Revision
The market is revising Upward the revenue expectations for BrightSpring Health Services, Inc. (BTSG) for FY2025, with the revenue forecasts being adjusted by 1.15% over the past three months. During the same period, the stock price has changed by -3.66%.
Revenue Estimates for FY2025
Revise Upward
+1.15%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+11.4%
In Past 3 Month
Stock Price
Go Down
-3.66%
In Past 3 Month
6 Analyst Rating
32.69% Upside
Wall Street analysts forecast BTSG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BTSG is 29.71 USD with a low forecast of 25.00 USD and a high forecast of 41.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
32.69% Upside
Current: 22.390
Low
25.00
Averages
29.71
High
41.00
32.69% Upside
Current: 22.390
Low
25.00
Averages
29.71
High
41.00
TD Cowen
Buy
maintain
$37 -> $41
2025-08-04
Reason
TD Cowen
Price Target
$37 -> $41
2025-08-04
maintain
Buy
Reason
TD Cowen raised the firm's price target on BrightSpring Health to $41 from $37 and keeps a Buy rating on the shares. The firm said the expected benefit from LDDs and generic conversions driving 2H adj. EBITDA growth are durable and are likely to benefit 2026 growth but it remains to be seen how 2H ultimately tracks.
TD Cowen
NULL -> Buy
initiated
$37
2025-06-23
Reason
TD Cowen
Price Target
$37
2025-06-23
initiated
NULL -> Buy
Reason
TD Cowen initiated coverage of BrightSpring Health with a Buy rating and $37 price target. The company, a leading oncology-focused specialty pharmacy and home health provider, is positioned to benefit from continued specialty growth and a generic wave driven by pharma's upcoming patent cliff, the analyst tells investors in a research note. The firm says its price target implies the shares trade at 15-times its adjusted EBITDA estimate for fiscal 2026.
BTIG
David Larsen
Buy
maintain
$25 -> $30
2025-05-29
Reason
BTIG
David Larsen
Price Target
$25 -> $30
2025-05-29
maintain
Buy
Reason
BTIG analyst David Larsen raised the firm's price target on BrightSpring Health to $30 from $25 and keeps a Buy rating on the shares as part of a broader research note in summary of presentations at the recent Boston Digital Health Summit. The firm is citing the fairly high drug price inflation rates, especially amongst specialty and oncology medications, as well as good volumes, especially in the post-acute environment in boosting its price target on BrightSpring.
Wells Fargo
Stephen Baxter
Overweight
maintain
$25 -> $27
2025-05-13
Reason
Wells Fargo
Stephen Baxter
Price Target
$25 -> $27
2025-05-13
maintain
Overweight
Reason
Wells Fargo analyst Stephen Baxter raised the firm's price target on BrightSpring Health to $27 from $25 and keeps an Overweight rating on the shares. The firm is updating the model following the Q1 2025 beat and guidance increase. Wells is also increasing Pharmacy estimates and refining Provider estimates.
UBS
A.J. Rice
Strong Buy
Maintains
$22 → $30
2025-01-29
Reason
UBS
A.J. Rice
Price Target
$22 → $30
2025-01-29
Maintains
Strong Buy
Reason
Morgan Stanley
Erin Wright
Buy
Maintains
$19 → $20
2024-12-17
Reason
Morgan Stanley
Erin Wright
Price Target
$19 → $20
2024-12-17
Maintains
Buy
Reason
Morgan Stanley analyst Erin Wright raised the firm's price target on BrightSpring Health to $20 from $19 and keeps an Overweight rating on the shares. Diversified Managed Care "woefully underperformed" in 2024 and while uncertainty is pressuring sentiment, the firm sees "opportunities in a friendlier policy backdrop," the analyst tells investors in a 2025 outlook note on the healthcare services group.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Brightspring Health Services Inc (BTSG.O) is 19.53, compared to its 5-year average forward P/E of 22.97. For a more detailed relative valuation and DCF analysis to assess Brightspring Health Services Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Fair
5Y Average PE
22.97
Current PE
19.53
Overvalued PE
29.60
Undervalued PE
16.35
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Overvalued
5Y Average EV/EBITDA
9.75
Current EV/EBITDA
11.09
Overvalued EV/EBITDA
10.88
Undervalued EV/EBITDA
8.61
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Overvalued
5Y Average PS
0.23
Current PS
0.34
Overvalued PS
0.29
Undervalued PS
0.17
Financials
Annual
Quarterly
FY2025Q2
YoY :
+29.10%
3.15B
Total Revenue
FY2025Q2
YoY :
+25.62%
48.56M
Operating Profit
FY2025Q2
YoY :
+0.65%
8.54M
Net Income after Tax
FY2025Q2
YoY :
+30.00%
0.13
EPS - Diluted
FY2025Q2
YoY :
-163.26%
24.65M
Free Cash Flow
FY2025Q2
YoY :
-6.95%
11.91
Gross Profit Margin - %
FY2025Q2
YoY :
+560.87%
1.52
FCF Margin - %
FY2025Q2
YoY :
-22.86%
0.27
Net Margin - %
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 162.33% over the last month.
Sold
0-3
Months
666.1M
USD
8
3-6
Months
0.0
USD
0
6-9
Months
253.9M
USD
1
0-12
Months
1,502.82T
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
2
258.7M
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
100.0K
Volume
1
6-9
Months
1.6M
Volume
3
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
75.0K
Volume
Months
6-9
1
450.0K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 162.33% over the last month.
Sold
0-3
Months
666.1M
USD
8
3-6
Months
0.0
USD
0
6-9
Months
253.9M
USD
1
0-12
Months
1,502.82T
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
2
258.7M
USD
Months
BTSG News & Events
Events Timeline
2025-08-01 (ET)
2025-08-01
06:12:48
BrightSpring Health sees FY25 revenue $12.200B-$12.600B, consensus $12.34B
2025-08-01
06:10:19
BrightSpring Health reports Q2 cont. ops. EPS 4c, consensus 19c
2025-07-01 (ET)
2025-07-01
09:52:23
Home health stocks under pressure following proposed rate cuts
Sign Up For More Events
Sign Up For More Events
News
9.5
08-02NASDAQ.COMBrightSpring (BTSG) Q2 Revenue Jumps 29%
9.5
08-01NewsfilterBrightSpring Health Services, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year 2025 Guidance
9.5
08-01NASDAQ.COMBrightSpring Health Services, Inc. Q2 Profit Increases, Beats Estimates
Sign Up For More News
People Also Watch
FBP
First BanCorp
21.480
USD
+1.13%
FA
First Advantage Corp
17.240
USD
+5.38%
WD
Walker & Dunlop Inc
84.610
USD
+1.61%
BXMT
Blackstone Mortgage Trust Inc
19.350
USD
+1.84%
HIW
Highwoods Properties Inc
29.700
USD
+2.59%
IPGP
IPG Photonics Corp
80.340
USD
+2.66%
SLVM
Sylvamo Corp
45.690
USD
+3.56%
IRDM
Iridium Communications Inc
24.980
USD
+0.36%
AVPT
AvePoint Inc
14.990
USD
+0.60%
FAQ
What is Brightspring Health Services Inc (BTSG) stock price today?
The current price of BTSG is 22.39 USD — it has increased 3.08 % in the last trading day.
What is Brightspring Health Services Inc (BTSG)'s business?
What is the price predicton of BTSG Stock?
What is Brightspring Health Services Inc (BTSG)'s revenue for the last quarter?
What is Brightspring Health Services Inc (BTSG)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Brightspring Health Services Inc (BTSG)'s fundamentals?
How many employees does Brightspring Health Services Inc (BTSG). have?